Adherence to Annual Lung Cancer Screening

Patient Adherence to Screening for Lung Cancer in the US

“…The length of follow-up ranged from 12 to 18 months, with 1 study 18 reporting data to 36 months. Only 3 studies 14,27,29 reported their funding sources.…”

“…Thirteen studies [12][13][14][15][16][17]19,20,22,23,[27][28][29] (87%) confirmed screening adherence through medical records or large database records. However, 12 studies 12,[14][15][16][17][18]20,22,23,25,27,28 (80%) did not have a follow-up time that was long enough to adequately assess periodic adherence beyond 1 year. All of the studies reported loss-to-follow-up rates greater than 20% (eTable 2 in the Supplement).…”

“…Fifteen studies (19 publications) involving a total of 16 863 individuals were included in this systematic review. 12 Ten studies were retrospective [12][13][14][15]17,19,[22][23][24][25][26][27] and 5 were prospective cohorts 16,18,20,21,[28][29][30] (Table 1). Eight studies 12,[17][18][19]23,25,27,28 were conducted in an academic setting and 7 [13][14][15][16]20,22,29 in a community setting.…”

“…12 Ten studies were retrospective [12][13][14][15]17,19,[22][23][24][25][26][27] and 5 were prospective cohorts 16,18,20,21,[28][29][30] (Table 1). Eight studies 12,[17][18][19]23,25,27,28 were conducted in an academic setting and 7 [13][14][15][16]20,22,29 in a community setting. Aside from 1 study, 18 adherence was evaluated for only the first subsequent screening.…”

Patient Experience of Managing Adherence to Repeat Lung Cancer Screening

“…The United States Preventive Services Task Force (USPSTF) recommends annual lung cancer screening (LCS) with low-dose computed tomography (LDCT) in adults aged 55 to 80 with a substantial history of smoking ( 1 ), but less than 15% of eligible individuals nationally initiate LCS ( 2 , 3 ). Of those who do, adherence to recommended follow-up or repeat screening is variable, ranging from 35% to 86% ( 4 – 8 ), and adherence decreases with subsequent rounds of screening. To achieve the goal of reducing lung cancer mortality, patients must continue to adhere to annual LCS and interim surveillance over many years.…”